Industries GUIDE
AI in Clinical Trials
AI is reshaping how new drugs are tested — finding eligible patients faster, predicting which trials will succeed, and catching safety signals sooner.
Listen to this guideAI-narrated · ~2 min
On this page2 min read
Overview
It targets one of medicine's biggest bottlenecks: trials are slow, expensive, and frequently fail.
Deep Dive
Bringing a drug to market can take over a decade and cost billions, with most trials failing partly because of poor patient recruitment and design. AI attacks these pain points. NLP systems read electronic health records to match patients to trial eligibility criteria far faster than manual chart review. Companies like Deep 6 AI and Tempus use this to accelerate enrollment. Machine learning helps optimize trial design — choosing sites, predicting dropout, and identifying biomarkers that define responder subgroups. AI also enables 'synthetic control arms,' using historical patient data to reduce how many people must receive a placebo. In monitoring, algorithms flag adverse events and data anomalies across thousands of records. Regulators including the FDA have issued draft guidance on AI's role, signaling both opportunity and the need for rigor.
Real-World Implementation
Deep 6 AI scans hospital EHRs with NLP to identify trial-eligible patients in minutes instead of weeks, speeding up enrollment.
Synthetic control arms built from historical patient records have been used (e.g., in oncology and rare-disease trials) to reduce the number of patients given placebo.
Machine-learning models predict patient dropout and underperforming sites so sponsors can intervene before a trial stalls.
AI pharmacovigilance tools scan trial and post-market data to detect adverse-event signals earlier than manual review.
The Future of AI in Clinical Trials
Expect AI to push toward faster, smaller, more adaptive trials — Bayesian adaptive designs that adjust dosing or arms mid-study, and decentralized trials using wearables for remote monitoring. Generative AI may auto-draft protocols, regulatory submissions, and patient-friendly consent forms. Synthetic and external control arms will grow where ethics make placebos hard, especially in rare diseases. The gating factor is validation and trust: regulators will require transparency, bias auditing, and proof that AI-selected endpoints and cohorts truly generalize.
Putting it into practice
Why it matters
- Context and rules. Industry context determines whether AI ideas survive contact with reality.
- Quality control. Domain constraints influence acceptable error rates and oversight models.
- Build choices. Successful deployments align technical capability with frontline workflows.
Watch out for
- Regulatory requirements can invalidate otherwise strong prototypes.
- Historical data may encode bias that harms specific communities.
- Legacy systems can create integration bottlenecks and hidden costs.
Next steps
- Involve domain experts from problem framing to evaluation.
- Design audit trails and documentation before launch.
- Validate compliance and safety obligations early.
- Roll out in phases with clear stop and rollback criteria.
Keep Exploring
Free newsletter
Keep up with AI in 3 minutes a day
One short email each weekday with the three AI stories that actually matter. Free forever, no ads.
One email each weekday. Unsubscribe in one click. We never sell or share your address.
Test yourself
Take the AI in Clinical Trials quiz
Instant feedback on every answer, and a shareable certificate with a verifiable ID once you pass a course.
Support free AI education. AI Understanding is a 501(c)(3) nonprofit — no ads, no paywall, ever. Make a donation
Frequently asked questions
What is AI in Clinical Trials?
AI is reshaping how new drugs are tested — finding eligible patients faster, predicting which trials will succeed, and catching safety signals sooner. It targets one of medicine's biggest bottlenecks: trials are slow, expensive, and frequently fail.
Which long-standing problem in clinical trials does AI most directly target?
Poor and slow patient recruitment is a major cause of trial delays and failures, and AI-driven matching is a leading remedy.
How can natural-language processing help screen patients for clinical trials?
Research on clinical trial matching uses NLP to extract patient information from EHR notes and compare it with free-text inclusion and exclusion criteria.
What is an external control arm in a clinical trial?
FDA defines an externally controlled trial as comparing treated participants with an external group; whether it can replace a concurrent control is context-dependent and requires careful comparability and bias assessment.
What can propensity-score matching do when constructing an external-control comparison?
Propensity scores can balance observed covariates under assumptions; they do not remove confounding from unmeasured variables or make noncomparable groups equivalent.
Why do predictive dropout and site-performance models matter to trial sponsors?
By forecasting which patients may drop out or which sites underperform, sponsors can act early to keep the trial on track.
Keep learning
Related guides
More guides picked for this topic